Clone:
REAL186
Type of antibody:
Releasable antibodies, Primary antibodies, Recombinant antibodies
Applications:
FC, MICS, IHC, IF
Alternative names:
FAS, ALPS1A, APO-1, Apt1, FAS1, FASTM, Tnfrsf6

Extended validation for CD95 (FAS) Antibody, anti-human,
REAlease
®

Specificity

Knockout validation
To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.
View details
Overlay histogram showing flow cytometric analysis of CD95 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD95-APC, clone (REAL186). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
Overlay histogram showing flow cytometric analysis of CD95 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD95-APC, clone (REAL186). Flow cytometry was performed with the MACSQuant
®
Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CD95 (FAS) Antibody, anti-human,
REAlease
®

Overview

Clone REAL186 is an antibody fragment derived from the full CD95 (FAS) antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL186 recognizes the human CD95 antigen, also known as FAS and Apo-1, which is a member of the tumor necrosis factor receptor superfamily (TNFR). CD95 is found on the surface of many normal and neoplastically transformed cells. Its ligand, CD95L (FASL/Apo-1L), is able to induce apoptosis in CD95-expressing cells upon binding. CD95 and CD95L are upregulated on lymphocytes upon activation and are known to play a key role in the regulation of an inflammatory response: Juxtocrine “fratricide” of neighbouring lymphocytes via mutual CD95 and CD95L expression helps to terminate immune responses, while apoptosis of pro-inflammatory cells via CD95 helps maintain immune privilege in sites such as the eye, where CD95L is found to be expressed in the retina and cornea.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.

Alternative names

FAS, ALPS1A, APO-1, Apt1, FAS1, FASTM, Tnfrsf6

Detailed product information

Technical specifications

CloneREAL186
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable antibodies, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenCD95 (FAS)
Alternative names of antigenFAS, ALPS1A, APO-1, Apt1, FAS1, FASTM, Tnfrsf6
Distribution of antigenlymphocytes
RRIDAB_2751242, AB_2784324, AB_2751243

References for CD95 (FAS) Antibody, anti-human,
REAlease
®

Publications

  1. Griffith, T. et al. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192
  2. Lynch, D. et al. (1995) Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 16: 569-574
  3. Pitcher, C. J. et al. (2002)
    Development and homeostasis of T cell memory in
    rhesus macaque
    .
    J. Immunol. 168: 29-43

Related products for
CD95 (FAS) Antibody, anti-human,
REAlease
®

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?